LAKE FOREST, Calif.--(ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, reported a high level of satisfaction from a group of 58 patients treated for presbyopia at the Ultralase Clinics in the United Kingdom with the Company’s proprietary Vue+® near vision inlay. Mark Wevill, M.D., MBChB, FRCSEd, FCS(SA), presented the data at the 2012 ACOS Femto and Presby Ophthalmic Solutions Cataract and Refractive Surgery Symposium (PresbyOscars) held in Cannes, France.)--
“These patient satisfaction rates are truly compelling and are very similar to those reported for LASIK”
The patient group included 31 males and 27 females ranging in age from 46 to 62 years. Each patient had paid for the procedure and was not part of a clinical study. The 15-minute outpatient procedures were performed by three different surgeons. Patients were implanted with the Vue+ in their non-dominant eye and data were accumulated from regular post-operative follow-up appointments at one to six months following the procedure. The patients were asked to summarize their feelings on their vision by selecting one of five options as part of the survey.
- 52% - Couldn’t Have Been Better
- 29% - Pleased With Results
- 12% - Satisfied
- 7% - Hoped For Better
- 0% - Regretted The Procedure
“These patient satisfaction rates are truly compelling and are very similar to those reported for LASIK,” said Dr. Wevill. “Following the Vue+ implant procedure, all patients were able to read 10-point typeface print found in many novels, 97% could read newspaper columns and 78% could read the 5-point typeface typically found in newspaper stock tables without corrective lenses.” Dr. Wevill was awarded Fellowship of the Royal College of Surgeons in 1995, has performed more than 13,000 laser eye surgery treatments and more than 2,000 procedures in his special interest area of cataract and intraocular surgery. He is an internationally recognized opinion leader in refractive surgery and has authored, presented and reviewed more than 30 scientific papers.
“We are excited to see the growing body of evidence of commercial patients who are pleased with their new vision. Whether it is the ‘WOW factor’ of being able to read again only days after the procedure, the convenience of not having to hunt for their reading glasses or simply the ‘no glasses’ look, Vue+ appears to be meeting or exceeding patient expectations,” said John T. Kilcoyne, RVO President and Chief Executive Officer.
The ReVision Optics patented near vision inlay technology has received CE Mark authorization under the trade name Vue+ and is available in the European Union, and is currently in a Phase 3 clinical trial in the United States under the name PresbyLens®. During the 15-minute procedure a clear, 2 mm circular corneal inlay is placed on the cornea that microscopically changes the shape of the surface of one eye. The lens is as transparent as natural tears and is less than half the thickness of a human hair. It is approximately 80% water and is bioengineered to facilitate transport of nutrients and fluid.
About Ultralase Clinics
Ultralase Clinics is the United Kingdom’s first and longest established vision correction provider, with 21 years of experience in the field. Ultralase has 30 locations, treating short-sight, long-sight, astigmatism, and presbyopia throughout the United Kingdom and Ireland. The management team leading Ultralase is comprised of highly skilled and experienced professionals, dedicated and totally focused on establishing and maintaining leadership in the UK’s vision correction market.
About ReVision Optics
ReVision Optics, Inc. focuses on the research and development of custom optical solutions dedicated to presbyopic vision correction. RVO’s first products, the Vue+® and PresbyLens® near vision inlays, both offer a unique patented refractive surgery solution. The inlays are designed to improve the near vision that has been lost by the eye’s natural aging process called presbyopia. The Vue+ and PresbyLens inlays are removable, and provide an ideally suited surgical option for near and intermediate vision enhancement.
The Company is actively pursuing regulatory approvals and market opportunities for the Vue+ and PresbyLens worldwide. The Vue+ and PresbyLens have received CE mark authorization and the Vue+ is available for sale in Europe.
*CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.